News
Researcher supports creation of database to improve maternal care in Nigeria
A university researcher has been part of a new project to establish an electronic healthcare database to improve maternity care in low and middle-income countries.
The Maternal and Perinatal Database for Quality, Equity and Dignity (MPD-4-QED) Programme in Nigeria has been established by the World Health Organisation, in collaboration with the Nigerian Federal Ministry of Health (FMOH), and was funded by the global initiative MSD for Mothers.
Dr Abiodun Adanikin, an assistant professor of maternal and perinatal epidemiology at Coventry University’s research centre for healthcare and communities, worked with colleagues to create the database.
The database serves as a monitoring tool for maternal and early neonatal care and outcomes and is the first of its kind in low and middle-income countries (LMICs).
“The challenge of quality data often plagues LMICs, preventing performance tracking and progress monitoring in maternity care,” said Dr Adanikin.
“While this database hasn’t been easy to accomplish, now we have a system which collects quality data.
“With periodic analysis, we can monitor the quality of maternity care and outcomes for women and babies and learn about what works and what can be improved. In addition, the data can be used for research purposes.”
What’s great about this database, Adanikin said, is that it can be replicated in other low- and middle-income countries that face the similar challenges of inequalities in maternity care outcomes as Nigeria.
“Many thanks to the outstanding teams and colleagues who collaborated on this project.
“Overall, the MPD-4-QED programme demonstrates substantial potential for tracking essential maternal, newborn and child health metrics in Nigeria – and potentially in other LMICs – rather than relying solely on estimates.”
Dr Adanikin recently shared the team’s experience and lessons learned in establishing the database in a publication in the British Journal of Obstetrics and Gynaecology.
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






